CLOPIDOGREL SG (Southern Cross Pharma Pty Ltd)
Product name
CLOPIDOGREL SG
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
45 working days (255)
Active ingredients
clopidogrel besilate
Registration type
EOI
Indication
Generic medicine
CLOPIDOGREL SG (tablets) is now also indicated for:
Acute Coronary Syndrome
Clopidogrel is indicated in combination with aspirin for patients with:
- Unstable angina or non-ST-elevation myocardial infarction in order to prevent early and long-termatherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). Clopidogrel is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or PCI, with or without stent).
- ST-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. In thispopulation, clopidogrel has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.